IntegraGen Announces Leading U.S. Cancer Center to Use MERCURY Cloud-based Tool for Oncology Sequencing Data Interpretation and Reporting
IntegraGen (Paris:ALINT), a company specializing in the transformation of data from biological samples into genomic information and diagnostic tools for oncology, today announced Dana-Farber Cancer Institute will utilize the company’s MERCURY cloud-based software as part of their analysis and reporting process for sequencing data obtained from tumors of cancer patients. Dana-Farber plans to utilize MERCURY to assist in the analysis of sequencing data obtained from small and large targeted gene sequencing panels as well as data derived from whole exome and genome sequencing.
“Genomic profiling of tumors can assist in the identification of pathogenic molecular alterations which drive a patient’s cancer and enable the implementation of precision medicine-based approaches to treatment,” stated Annette S. Kim M.D., Ph.D., Co-Director of the Dana-Farber Cancer Institute’s new Interpretive Genomics Program within the Department of Oncologic Pathology. The program is Co-Directed by Keith L. Ligon, MD PhD, Director of the Dana-Farber Center for Patient Derived Models. “MERCURY provides us with a tool to rapidly interpret large scale and complex genomic sequencing data with the added ability of customization to meet our specific analysis and reporting needs to support clinical research and clinical trials.”
“IntegraGen is excited about Dana-Faber’s decision to utilize MERCURY and look forward to interacting with another world leader in cancer care related to the utilization of our cloud-based bioinformatic tools,” said Larry Yost, General Manager of IntegraGen, Inc. “We are convinced that the use of MERCURY will aid in the better understanding of the etiology of a patient’s cancer and assist with the realization of the benefits of precision medicine by transforming large-scale sequencing data into actionable results. We are also looking forward to continuing the development and expansion of our genomic interpretation software tools in North America.”
MERCURY is a user-friendly genomic interpretation tool for oncology designed to assist pathologists and oncologists to rapidly transform raw data obtained via high-throughput sequencing into a clinical molecular report for clinical and research use. The cloud-based tool minimizes the complexity, time and cost associated with the clinical interpretation and identification of variants that may be of interest in the therapeutic management of patients. MERCURY utilizes the Google Cloud technology to ensure a secure environment for data analysis and storage which is compliant with the latest information security requirements.
IntegraGen is a company specializing in the analysis of the human genome and performs adaptive and quickly interpretable analyses for academic and private laboratories. For the management of cancers, which are characterized by a genetic disruption of cells, IntegraGen provides researchers and doctors with universal and individualized therapeutic guidance tools allowing them to adapt the treatment to the patient's genetic profile.
IntegraGen has forty-six employees and generated revenue of € 8.3 million in 2019. Based in the Génopole d'Evry, IntegraGen is also located in the United States in Cambridge, MA. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 - Mnemo: ALINT - Eligible PEA-PME).
For more information, visit www.integragen.com
Integragen Aktie jetzt ab 0€ handeln - auf Smartbroker.de